Publikationen

Günther A, Berg D, Joachimski F, Ragoschke-Schumm A, Redecker C. Neurological picture. Acute Wernicke's encephalopathy with hyperechogenic corpora mammillaria in brain sonography. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):114-5.

Reimann M, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schoels L, Reichmann H, Berg D, Ziemssen T. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm. 2010 Jan;117(1):69-76.

Lücking CB, Lichtner P, Kramer ER, Gieger C, Illig T, Dichgans M, Berg D, Gasser T. Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany. Neurobiol Aging. 2010 Jan;31(1):167-8.

Synofzik M, Asmus F, Reimold M, Schöls L, Berg D. Sustained dopaminergic response of Parkinsonism and depression in POLG-associated Parkinsonism. Mov Disord. 2009 Dec 7. [Epub ahead of print]

Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord. 2009, 24 Suppl 2:S677-83.

Mänz C, Godau J, Berg D, Bender B, Ernemann U, Klose U. The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri. Neuroradiology. 2009 Oct 27. [Epub ahead of print]

Walter U, Skoloudík D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci. 2009 Sep 5. [Epub ahead of print]

Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, Dillmann U, Gaenslen A, Di Santo A, Maetzler W, Berg D. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging. 2009 Nov 6. [Epub ahead of print]

Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009 Dec;8(12):1158-71.

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.

Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C,et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009 Dec;41(12):1308-12.

Schmidt C, Berg D; Herting, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Ziemssen T. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009 Oct 30;24(14):2136-42.

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, da Costa CA, Riess O. Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics. 2009 Sep 3. [Epub ahead of print]

Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord. 2009 Oct 30;24(14):2104-11.

Funke C, Soehn AS, Tomiuk J, Riess O, Berg D. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm. 2009 Apr;116(4):443-50.

Funke C, Tomiuk J, Riess O, Berg D, Soehn AS. Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm. 2009 Jul;116(7):853-9.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm. 2009 Jul;116(7):875-80.

Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage. 2009 Oct 1;47(4):1237-43.

Guthoff M, Tschritter O, Berg D, Liepelt I, Schulte C, Machicao F, Haering HU, Fritsche A. Effect of genetic variation in Kv1.3 on olfactory function. Diabetes Metab Res Rev. 2009 Sep;25(6):523-7.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[(18)F]FDG-PET. Mov Disord. 2009 Jul 30;24(10):1504-11.

Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord. 2009 Aug;15(7):539-41.

Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D. A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm. 2009 May;116(5):599-605.

Sharma M, Lichtner P, Kruger R, Berg D, Schulte C, Illig T, Riess O, Gasser T. Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging. 2009 Oct;30(10):1706-9.

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009 Aug;35(2):296-301.

Godau J, Manz A, Wevers AK, Gaenslen A, Berg D. Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord. 2009 Jan 15;24(1):133-7.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009 Apr;34(1):107-12.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Reichmann H, Berg D, Ziemssen T.Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord. 2008 Oct 30;23(14):2083-9.

Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Berg D, Reichmann H, Ziemssen T. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm. 2008 Nov;115(11):1527-36.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D, Ziemssen T. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord. 2008 Sep 15;23(12):1766-72.

Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008 Nov;7(11):1044-55.

Kamm C, Fogel W, Wächter T, Schweitzer K, Berg D, Kruger R, Freudenstein D, Gasser T. Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology. 2008 Apr 15;70(16 Pt 2):1501-3.

Schroeder C, Walter M, Berg D, Leitner P, Bauer P, Kohl Z, Winkler J, Riess O, Bonin M. High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. J Mol Diagn. 2008 May;10(3):217-24.

Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis. 2008;5:133-6.

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla H.-J., Reimold M, Marek K, Berg D. Prospective evaluation of the specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2008 May;7(5):417-24.

Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome, Mov Disord. 2008 Jun 15;23(8):1184-7.

Liepelt I, Wendt A, Schweitzer K.J., Wolf B, Godau J, Gaenslen A, Bruessel T, Berg D. Substantia nigra hyperechogenicity assessed by Transcranial Sonography is related to neuropsychological impairment in the elderly population. J Neural Transm. 2008 Jul;115(7):993-9.

Unger MM, Möller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Hoeffken H, Mayer G, Oertel WH. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord. 2008 Mar 15;23(4):596-9.

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1456-60.

Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol. 2008 May;255(5):643-8.

Gaenslen A, Gasser T, Berg D. Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm. 2008 115(5):703-13.

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-33.

Godau J, Wevers AK, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med. 2008 Oct;9(7):782-9.

Schweitzer KJ, Berg D. Transcranial ultrasound as a new instrument in the early and differential diagnosis of Parkinson's disease. CNS Drugs. 2007;21:17-24.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment for dementia in parkinsonian syndromes: Efficacy of cholinesterase inhibitors. Nervenarzt. 2008; 79:36-46.

Berg D. Ultrasound in the (premotor) diagnosis of Parkinson's disease. Parkinsonism Relat Dis. 2007;13:429-433.

Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Antoni S, Ferger D, Reichmann H, Wilhelm H, Berg D, Ziemssen T.Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord. 2007;22:2123-6.

Berg D. Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson's Disease: Implications for Idiopathic and Monogenetic Forms. Neurochem Res. 2007;32:1646-54.

Ruprecht-Dörfler P, Klotz P, Becker G, Berg D. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord. 2007;13:362-4.

Althaus A, Kanis T, Spottke A, Eggert K, Liepelt I, Berg D, Schneider F & Dodel R. Benchmarking in der Patientenversorgung, Depression bei der Parkinson-Krankheit - Ergebnisse der Pilotstudie. Nervenheilkunde 2007;26:277-80.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. Dement Geriatr Cogn Disord. 2007;23:351-367.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Muller A, Gasser T, Berg D. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm. 2007 Sep;114(9):1167-71.

Schweitzer KJ, Brussel T, Leitner P, Kruger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.J Neurol. 2007;254:613-6.

Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007;25:473-82.

Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22:187-192.

Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol. 2007;33:15-25.

Schols L, Nagele T, Schule R, Berg D. Cerebrotendinous xanthomatosis. Neurology. 2006;67:E20.

Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm. 2006; Suppl 71:123-32.

Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord. 2006 Sep;21(9):1299-310.

Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord. 2006; 21:1763-65.

Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U, Behnke S, Riess O, Berg D. Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett. 2006 Oct 16;407(1):16-9.

Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006;17:5-17.

Berg D, Behnke S, Walter U. Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations. Ultraschall Med. 2006;27:12-19.

Berg D, Hochstrasser H, Schweitzer K, Riess O. Disturbance of iron metabolism in Parkinson's disease - Ultrasonography as a biomarker. Neurotox Res. 2006; 9:1-13.

Schweitzer, K, Hilker, R, Walter, U, Burghaus, L, Berg, D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord. 2006;21:94-8.